Featured Research

from universities, journals, and other organizations

Testing Drug's Ability To Reverse Stroke After Standard Three-hour Window Has Closed

Date:
April 21, 2004
Source:
Northwestern Memorial Hospital
Summary:
Ischemic stroke patients who arrive at the hospital too late to receive currently available treatment options might someday have a new treatment option.

Ischemic stroke patients who arrive at the hospital too late to receive currently available treatment options might someday have a new treatment option. Northwestern Memorial Hospital is the only site in Chicago to participate in a phase III trial of abciximab (ReoPro - Centocor/Eli Lilly and Company), which seeks to determine the drug's ability to improve neurological function and minimize disability in patients who present with an acute ischemic stroke.

"tPA is the only FDA-approved treatment for ischemic stroke within three hours of onset, but most patients can't be treated with it because they arrive in the emergency department more than three hours after their stroke occurred," explains Richard Bernstein, M.D., Ph.D., a stroke neurologist at Northwestern Memorial Hospital and assistant professor of neurology at the Northwestern University's Feinberg School of Medicine. "Preliminary results with abciximab suggest we may be able to use it to extend this time window to six hours and possibly use it to treat the many patients who wake up from sleep with a stroke. Currently, there is no approved acute treatment for these patients and abciximab may represent a new approach."

Abciximab prevents blood platelets from forming clots, and also helps diminish clots that have already formed. Since ischemic stroke results from clots that block arteries supplying blood to the brain, it makes sense to test this agent in stroke. The research study currently underway, called AbESTT-II, is a randomized, double blind, placebo controlled trial of abciximab in acute stroke. It is sponsored by Eli Lilly and Centocor, and seeks to enroll 1,800 participants worldwide.

Unlike other investigational treatments to open blocked arteries in stroke beyond three hours, abciximab can be given into a vein in the arm and requires no additional invasive procedures. "Abciximab has been used for years by cardiologists to help keep diseased coronary arteries open," explains Dr. Bernstein. "If this treatment proves safe and effective in acute stroke, it could be used in any emergency room throughout the country. This could fundamentally change the way we treat this common and devastating disease."

Participants are potentially eligible for this trial if they can receive study drug or placebo within 6 hours of stroke onset, or if they wake up from sleep with a stroke and can receive study drug or placebo within three hours of waking up.

An acute stroke occurs when a blood vessel becomes blocked in the brain. This blockage prevents oxygen and nutrients in the blood from getting to part of the brain, resulting in the death of that part of the brain. Blood clots are formed when cells called platelets bind to each other and to other blood components. Since permanent damage can be done to the brain the longer it does not get blood and oxygen, it is important to restore blood flow as quickly as possible.

Stroke is the third leading cause of death worldwide, resulting in approximately five million deaths every year. It is the leading cause of adult long-term disability. About 85 percent of all strokes are termed ischemic, meaning they are caused by a blood clot or plaque that blocks a blood vessel in the brain.


Story Source:

The above story is based on materials provided by Northwestern Memorial Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern Memorial Hospital. "Testing Drug's Ability To Reverse Stroke After Standard Three-hour Window Has Closed." ScienceDaily. ScienceDaily, 21 April 2004. <www.sciencedaily.com/releases/2004/04/040414004907.htm>.
Northwestern Memorial Hospital. (2004, April 21). Testing Drug's Ability To Reverse Stroke After Standard Three-hour Window Has Closed. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/04/040414004907.htm
Northwestern Memorial Hospital. "Testing Drug's Ability To Reverse Stroke After Standard Three-hour Window Has Closed." ScienceDaily. www.sciencedaily.com/releases/2004/04/040414004907.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins